These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35170548)

  • 1. Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer.
    Mu B; Zhang R; Pu Y; Yao J; Hu X; Zhao C
    Eur J Cancer Prev; 2023 Jan; 32(1):65-68. PubMed ID: 35170548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer.
    Liu Z; Gu X; Li Z; Shan S; Wu F; Ren T
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3563-3573. PubMed ID: 35960376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.
    Xu X; Zhang J; Yao T; Zhao X; Wu Q; Lu C; Guo X; Xie S; Qiu L; Bi R; Xue H
    Int Immunopharmacol; 2024 Sep; 139():112727. PubMed ID: 39067405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.
    Zhang Z; Geng X; Yin M; Zhang S; Liu Y; Hu D; Zheng G
    World J Surg Oncol; 2024 Oct; 22(1):273. PubMed ID: 39390580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer.
    Ilikci Sagkan R; Akin-Bali DF
    J Med Virol; 2020 Nov; 92(11):2637-2647. PubMed ID: 32492203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.
    Kong Q; Xiang Z; Wu Y; Gu Y; Guo J; Geng F
    Mol Cancer; 2020 Apr; 19(1):80. PubMed ID: 32345328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinoma.
    Liu Z; Lu Q; Zhang Z; Feng Q; Wang X
    Respir Res; 2024 Jun; 25(1):238. PubMed ID: 38862975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
    Tuna M; Mills GB; Amos CI
    Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.